SCHEMBL6345855

SCHEMBL6345855

NC(=O)c1nn(-c2ccc(S(N)(=O)=O)cc2)c2c1ccc1ccc(NS(=O)(=O)c3cccc(Cl)c3)cc12

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 3/20 0.44
PTGS1 P23219 2/20 0.44
CA1 P00915 7/20 0.43
CA2 P00918 7/20 0.43
CA4 P22748 4/20 0.43
CA7 P43166 3/20 0.43
PGR P06401 4/20 0.41
KDR P35968 1/20 0.41
PKM P14618 1/20 0.41
CA9 Q16790 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CA12 O43570 2/20 0.40
TP53 P04637 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TSHR P16473 1/20 0.40
BRD4 O60885 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6353535 0.90 MAPK1 (0.44) PTGS2PTGS1CA1CA2CA4
SCHEMBL6352174 0.90 HSD17B2 (0.43) PTGS2PTGS1CA1CA2CA4
SCHEMBL6352252 0.89 PTGS2 (0.43) PTGS2PTGS1CA1CA2CA4
SCHEMBL6354591 0.87 CA2 (0.47) PTGS2PTGS1CA2PGRTSHR
SCHEMBL6344422 0.86 PTGS2 (0.42) PTGS2PTGS1CA1CA2CA4
SCHEMBL6342797 0.85 PTGS2 (0.48) PTGS2PTGS1CA1CA2CA4
SCHEMBL6341929 0.85 PTGS2 (0.43) PTGS2PTGS1CA1CA2CA4
SCHEMBL6345751 0.83 CA1 (0.44) PTGS2PTGS1CA1CA2CA4
SCHEMBL6355132 0.82 CA2 (0.42) PTGS2PTGS1CA1CA2CA4
SCHEMBL6344535 0.81 KMT2A (0.54) PTGS2PTGS1CA1CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1438293-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2004-07-21 EP claimed
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-07-03 US claimed
WO-2003027075-A2 SUBSTITUTED PYRAZOLYL BENZENESULFAMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2003-04-03 WO claimed
US-6849653-B2 1H-benzo(g)indazole compounds as anticarcinogenic agents and also treat arthritis PHARMACIA CORPORATION (US) 2005-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030125361-A1 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation IRAK4, NLRP3, CXCL8 PTGS2 37/4885PTGS1 29/4885CA1 3893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.